Nvwm LLC Has $960,000 Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Nvwm LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,384 shares of the pharmaceutical company’s stock after selling 23 shares during the quarter. Nvwm LLC’s holdings in Vertex Pharmaceuticals were worth $960,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Northwest Investment Counselors LLC acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at $25,000. Dunhill Financial LLC lifted its holdings in Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 24 shares in the last quarter. Highline Wealth Partners LLC acquired a new position in Vertex Pharmaceuticals in the third quarter valued at about $27,000. Legacy Investment Solutions LLC bought a new stake in shares of Vertex Pharmaceuticals in the third quarter worth about $33,000. Finally, Brown Lisle Cummings Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth about $30,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Up 2.5 %

VRTX stock opened at $482.28 on Wednesday. The business’s 50 day simple moving average is $435.03 and its 200 day simple moving average is $462.56. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The firm has a market capitalization of $124.20 billion, a PE ratio of -242.35, a PEG ratio of 2.39 and a beta of 0.41. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.77. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the firm earned $3.67 earnings per share. As a group, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.93 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on VRTX. UBS Group increased their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Bank of America lowered their price objective on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research report on Thursday, December 19th. StockNews.com cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 21st. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Finally, HC Wainwright upped their price objective on Vertex Pharmaceuticals from $535.00 to $550.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $502.58.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.